Neuronal epigenetics specialist Rodin Therapeutics Inc. has completed a $27 million financing that will fund its soon-to-be-chosen lead histone deacetylase 2 (HDAC2) inhibitor through a phase Ib proof-of-concept study in Alzheimer's disease (AD). A multimillion-dollar R&D and option deal it struck with Biogen Inc., however, is dead, terminated by mutual agreement, Rodin's president and CEO, Adam Rosenberg, told BioWorld.